GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ImageneBio Inc
Ikena Oncology, a biotech focused on targeted cancer therapy, shares reflect the progress of its clinical programs. Their price is highly volatile and depends on research results, partnerships, and the potential of its scientific platform.
Share prices of companies in the market segment - Pharma immune
Ikena Oncology (ticker IKNA, not IMA) is a biopharmaceutical company developing targeted therapies for the treatment of oncological diseases mediated by the Hippo and RAS signaling pathways. We classify it as an "Immune Pharmaceuticals" company. The chart below shows the dynamics of this segment.
Broad Market Index - GURU.Markets
Ikena Oncology is an oncology company developing targeted drugs for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Ikena shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IMA - Daily change in the company's share price ImageneBio Inc
For ImageneBio Inc (IKENA Oncology), the daily price change is a measure of the extreme volatility inherent in biotech. It reflects investor reaction to news about oncology clinical trials and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
ImageneBio Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMA's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ImageneBio is a biotech company focused on immunology and oncology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ImageneBio Inc
ImageneBio, operating under the Ikena Oncology brand, has been a true story of targeted cancer drug development for the past year. Its 12-month market cap is entirely dependent on the progress of its candidates in clinical trials. Its partnership with Bristol Myers Squibb is a key validation of the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
Ikena, as a biotech company, focuses on targeted oncology. Its performance is completely separate from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique scientific developments for cancer treatment.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
The ticker symbol IMA belongs to Imax Corp, not ImageneBio. ImageneBio (Ikena Oncology, IKNA) is a biotech whose stock performance is entirely dependent on clinical trial results. Its chart isn't about economics, but about binary outcomes in the world of cutting-edge science and medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a clinical-stage oncology company. Its monthly performance is determined by developments in its R&D pipeline. Data from clinical trials of its targeted therapies is a key catalyst for dramatic changes in investor valuations.
Monthly dynamics of market capitalization of the market segment - Pharma immune
ImageneBio, formerly Ikena Oncology, is a biopharmaceutical company focused on the discovery and development of targeted therapies for cancer treatment. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its scientific platform, focused on new oncology targets, is progressing through clinical development.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ImageneBio (Ikena Oncology) is a company operating in the field of immuno-oncology. Its shares, like most biotech companies, are influenced by news about clinical trials. The chart shows that monthly price fluctuations are a response to company-specific events, not to the overall market situation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ImageneBio Inc
ImageneBio, a biotech company specializing in immuno-oncology, exhibits high volatility. Its weekly stock price performance reflects news about clinical trials, scientific data, and partnerships, typical of companies operating at the cutting edge of science.
Weekly dynamics of market capitalization of the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) focuses on developing targeted cancer therapies. Clinical trial news is a key driver for such companies. This chart allows us to separate the unique stock dynamics associated with scientific data from the overall sentiment in the immuno-oncology sector and assess its relative strength.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ImageneBio (formerly Ikena Oncology) is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart shows that IMA's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
IMA - Market capitalization of the company ImageneBio Inc
ImageneBio's market cap is a financial roadmap for precision oncology. This biotech company's stock price reflects its hopes for developing targeted cancer treatments based on a deep understanding of tumor biology. Its performance is a barometer of its research progress and faith in the future of personalized medicine.
IMA - Share of the company's market capitalization ImageneBio Inc within the market segment - Pharma immune
ImageneBio's (Ikena Oncology) market share in the immuno-oncology sector reflects its focus on targeted cancer therapies. Its market share is based on the potential of its pipeline of developments targeting specific molecular pathways in cancer cells. This is a bet on the future of personalized oncology.
Market capitalization of the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotech company focused on cancer immunotherapy. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the enormous investment and hopes associated with the discovery of new cancer treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
ImageneBio is an oncology company developing targeted drugs for cancer treatment. Its market capitalization reflects the potential of its research and development pipeline. The chart below shows the economic weight of biotech companies working on smart drugs.
Book value capitalization of the company, segment and market as a whole
IMA - Book value capitalization of the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company. Its book value is its R&D capital. The chart below shows financial resources, not manufacturing facilities. Its level is an indicator of the company's ability to finance its cancer drug development programs.
IMA - Share of the company's book capitalization ImageneBio Inc within the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotech company developing targeted cancer therapies. Its primary asset is research and development. The company's tangible asset share chart will be low, reflecting its focus on R&D, with laboratories serving as its primary assets rather than large manufacturing facilities.
Market segment balance sheet capitalization - Pharma immune
ImageneBio (part of Ikena Oncology) is a biotech company whose value is created in laboratories developing cancer treatments. It's a "light" model, based on science. The chart below shows how much the pharmaceutical industry relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
ImageneBio's (formerly Ikena Oncology) balance sheet is capital focused on developing targeted oncology drugs to combat cancers caused by specific mutations. The book value chart shows the amount of resources devoted to this cutting-edge area of personalized medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ImageneBio Inc
ImageneBio (likely Ikena Oncology) is a biotech focused on targeted cancer therapy. Its book value represents cash in its accounts. Its market capitalization is a valuation of its scientific platform and the potential of its candidate molecules. The chart reflects how the market weighs the chances of success for its research in the highly competitive field of oncology.
Market to book capitalization ratio in a market segment - Pharma immune
ImageneBio (likely Ikena Oncology) is a biopharmaceutical company focused on oncology. Its value is derived from its pipeline of promising developments. The chart clearly demonstrates how its market capitalization, based on expectations of clinical trial success, is many times greater than its book value.
Market to book capitalization ratio for the market as a whole
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted cancer therapies. The chart shows how the market values the scientific approach to creating precision medicines. The company's market capitalization reflects investors' bets on the success of its candidate molecules in clinical trials, which is typical for innovative biotech companies.
Debts of the company, segment and market as a whole
IMA - Company debts ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company focused on targeted oncology. Funding parallel clinical trial programs requires significant resources. This chart shows how the company uses raised capital, including debt, to advance its drug portfolio.
Market segment debts - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company focused on targeted cancer therapy. Their approach is based on a deep understanding of tumor biology. The chart shows common financial metrics for the biotech sector, which can be used to assess how the company finances its portfolio of early-stage precision oncology programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted cancer therapies. This chart shows the proportion of debt financing its lengthy and expensive research. This is a key indicator of financial risk for a company whose success depends on the outcome of unpredictable clinical trials.
Market segment debt to market segment book capitalization - Pharma immune
Developing targeted cancer treatments, a focus of ImageneBio (formerly Ikena Oncology), requires significant R&D investments. This chart shows how the biotech sector funds its research. It allows one to assess how the financial model of a company focused on precision oncology compares to the overall debt policy of this knowledge-intensive industry.
Debt to book value of all companies in the market
ImageneBio (IKENA Oncology) is a biotech company focused on developing targeted cancer therapies. The long journey from lab to patient requires significant financing. This chart allows us to assess the company's debt load in the context of the overall market, reflecting the balance between risk and potential breakthrough.
P/E of the company, segment and market as a whole
P/E - ImageneBio Inc
This metric for ImageneBio Inc (formerly Ikena Oncology), a biopharmaceutical company focused on targeted oncology, reflects future expectations. Its value is determined not by current profits, but by investors' faith in its scientific approach to developing drugs for precisely defined patient groups.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which ImageneBio operates. In this industry, filled with research-stage companies, the average earnings valuation is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs in oncology.
P/E of the market as a whole
ImageneBio (formerly Ikena Oncology) is a biotech company developing targeted drugs for cancer treatment. It focuses on specific molecular targets, enabling the creation of personalized therapies. This chart shows the market's risk appetite, allowing investors to understand how the company's scientific approach and its chances of success in specific oncology programs are assessed.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted cancer therapies that target specific tumor signaling pathways. Its future depends on the success of clinical trials. This chart reflects investor expectations for its scientific approach to creating personalized cancer treatments.
%20P%2FE%20ImageneBio%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ImageneBio-Inc&v=1772513546673 "Chart of the company's future (projected) P/E ImageneBio Inc")
Future (projected) P/E of the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotech company focused on targeted cancer therapy. It focuses on specific signaling pathways in cancer cells to create more precise drugs. This chart reflects expectations for the biotech sector, allowing you to assess how the market views the company's scientific platform and development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513546711 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted drugs for cancer treatment. Their approach is based on a deep understanding of tumor biology. This chart of overall expectations shows the market's willingness to fund science. Investor optimism and risk appetite are essential for raising funds for lengthy and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513546758 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a clinical-stage biotech company focused on targeted cancer therapy. This chart shows the cost of developing precision-guided oncology drugs. Profits are negative during the research stage, and financial results reflect progress in clinical trials and partnerships with major pharmaceutical companies.
Profit of companies in the market segment - Pharma immune
RedCloud Holdings is likely a retail or consumer technology company. Its profitability will depend on its specific business model. This chart reflects general trends in retail, where competition, supply chain management, and consumer insight are universal keys to achieving and maintaining profitability.
Overall market profit
ImageneBio, formerly Ikena Oncology, is a biotech company focused on developing targeted therapies for the treatment of cancer. Currently in clinical trials, its value is determined by the scientific potential of its developments. It is an example of a business whose trajectory can change dramatically after data is published, regardless of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted oncology drugs for the treatment of cancer. Its revenue outlook is long-term and depends on the success of clinical trials. This chart reflects analyst expectations for the company's scientific platform and its ability to develop new drugs for patients with specific genetic mutations.
%20profit%20of%20the%20company%20ImageneBio%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ImageneBio-Inc&v=1772513547118 "Graph of future (projected) profit of the company ImageneBio Inc")
Future (predicted) profit of companies in the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted drugs for cancer treatment. Its approach is based on a deep understanding of cancer cell signaling pathways. This chart shows profitability forecasts for the oncology sector. It reflects expectations for the development of personalized medicine in the fight against cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513547330 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
ImageneBio (formerly Ikena Oncology) develops targeted therapies for cancer. The company's success depends on the results of clinical trials. However, the overall economic climate, reflected in the total revenue projections in this chart, determines the availability of venture capital and the interest of large pharmaceutical companies in partnerships or acquisitions.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513547414 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted cancer treatments. Being in the clinical stage, it has no commercial revenue. The valuation, as shown in the chart, is based entirely on investors' faith in its scientific approach to developing new oncology drugs and the potential of its developments.
P/S market segment - Pharma immune
ImageneBio Inc., trading as Ikena Oncology, is a clinical-stage biotechnology company developing targeted cancer therapies with novel biological targets. This chart shows the average valuation in the sector, providing insight into the market's perception of the revenue potential of Ikena's innovative approach to oncology.
P/S of the market as a whole
ImageneBio, formerly Ikena Oncology, is a biotech company focused on developing targeted therapies for cancer treatment. Its approach is based on a deep understanding of tumor biology. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs rather than on current cash flows.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted therapies for cancer treatment. This chart shows how investors assess the future potential of its pipeline. This assessment is based on expectations of successful clinical trials and potential partnerships to bring new drugs to market.
%20P%2FS%20ImageneBio%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ImageneBio-Inc&v=1772513547778 "The graph of the company's future (projected) P/S ImageneBio Inc")
Future (projected) P/S of the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted therapies for the treatment of cancers caused by specific mutations. This chart shows the premium investors are willing to pay for the company's future sales, reflecting the high potential of its developments in the field of personalized medicine.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513547845 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Investor optimism about future revenue depends on progress in cancer treatment. ImageneBio (formerly Ikena Oncology) focuses on developing targeted therapies for specific genetic mutations in tumors. Their scientific approach reflects the trend toward personalized oncology, which promises more effective treatment and is driving growth for the entire industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513547906 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. Currently, its revenue is generated not from sales but from upfront fees and fees under collaboration agreements. This chart reflects progress in research and partnerships.
Sales of companies in the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company focused on developing targeted cancer therapies for patients with specific genetic mutations. This chart reflects overall revenue in the immunology pharmaceutical sector. It illustrates the shift toward personalized medicine, where ImageneBio develops treatments for specific patient groups.
Overall market sales
ImageneBio (formerly Ikena Oncology) is a biotech company focused on targeted oncology, developing drugs that target specific mutations in cancer cells. Its future depends on the success of clinical trials. This graph of the overall economic climate impacts the availability of funding for biotech companies and the overall risk assessment in the sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted therapies for oncology. Its future depends on the success of clinical trials. The chart shows analysts' speculative revenue forecasts, which are a bet on the company proving the effectiveness of its drug candidates.
%20sales%20of%20the%20company%20ImageneBio%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ImageneBio-Inc&v=1772513548053 "Schedule of future (projected) sales of the company ImageneBio Inc")
Future (projected) sales of companies in the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its approach is based on identifying specific biomarkers in patients. This chart displays projected sales for the entire immunological pharmaceutical segment, highlighting overall growth expectations for this cutting-edge field in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513548070 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
ImageneBio (formerly Ikena Oncology) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology. Its future depends on the success of clinical trials. This overall economic activity profile influences the overall investment climate, which determines the availability of capital for funding long-term R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513548093 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted cancer therapies. This indicator reflects the company's financial progress through the clinical trial stage. It demonstrates the level of R&D investment required to bring a new generation of drugs to market and achieve commercial success.
Market segment marginality - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. Its financial performance reflects its focus on clinical research. This chart provides insight into its operating model and level of investment in research compared to other immuno-oncology companies.
Market marginality as a whole
ImageneBio (formerly Ikena Oncology) is a clinical-stage biotech company focused on developing targeted therapies for cancer treatment. Their approach is based on a deep understanding of tumor biology. Their success depends on clinical trial results. This overall profitability curve is influenced solely by the general availability of funding in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company ImageneBio Inc
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted therapies for oncology. Currently in the clinical stage, its core scientific team forms the core. This graph shows the dynamics of the scientific team, whose growth reflects progress in research and the advancement of several programs into clinical trials.
Share of the company's employees ImageneBio Inc within the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) focuses on targeted oncology, developing small molecules against cancer signaling pathways. This chart shows the proportion of molecular oncology and bioinformatics scientists the company employs. Its team is at the forefront of identifying the Achilles' heel of tumor cells.
Number of employees in the market segment - Pharma immune
ImageneBio Inc., formerly Ikena Oncology, is a biotechnology company focused on developing targeted therapies for cancer treatment. This chart shows overall employment in the immunology research sector. It illustrates how science is moving toward increasingly precise targeting of cancer cells, which requires deep expertise in molecular biology and genetics.
Number of employees in the market as a whole
ImageneBio (formerly Ikena Oncology) is a biotechnology company focused on developing targeted therapies for cancer. Its approach is based on a deep understanding of cancer cell biology. This chart illustrates the dynamics of the labor market, where the knowledge-intensive biotechnology sector constantly demands an influx of talented scientists to create breakthrough treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ImageneBio Inc (IMA)
ImageneBio Inc. (formerly Ikena Oncology) is a biopharmaceutical company focused on developing targeted cancer therapies. This chart is a classic example of biotech. The extremely high market capitalization per employee suggests that the market values not current operations but the potential of scientific research and intellectual property developed by a small team of scientists.
%20of%20the%20company%20ImageneBio%20Inc%20(IMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ImageneBio-Inc-IMA&v=1772513548282 "Chart of market capitalization per employee (in thousands of dollars) of the company ImageneBio Inc (IMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted therapies for oncology. Their value is determined solely by the potential of their research and development. This metric demonstrates the enormous value the market places on their intellectual property. A high value reflects investors' bet on the future success of their drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513548316 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
ImageneBio Inc (likely Ikena Oncology) is a biopharmaceutical company focused on developing targeted cancer therapies. Its value is determined by the potential of its research programs. This metric is typical for biotech, where market capitalization reflects not current revenue but the expectations of future breakthroughs created by a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513548422 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ImageneBio Inc (IMA)
Ikena Oncology (IKNA) is a clinical-stage biotech company focused on targeted cancer therapies. Their business model is 100% research and development. This chart shows the "cost" of this research: it measures the net loss (R&D costs) per scientist working on their oncology programs.
%20Chart%20ImageneBio%20Inc%20(IMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ImageneBio-Inc-IMA&v=1772513548442 "Company Profit Per Employee (in thousands of dollars) Chart ImageneBio Inc (IMA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Ikena Oncology (IMA) is a clinical-stage biopharmaceutical company focused on targeted cancer therapy. Like most biotech companies in R&D, this indicator is currently negative. This chart provides a guide to the future. Success will depend on whether their scientific team can develop a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513548456 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
ImageneBio (IMA) (likely Ikena Oncology, IKNA) is a biotech company specializing in targeted oncology. They develop small-molecule drugs that target specific cancer mutations. This graph shows the typical picture for an R&D company: negative profit per employee, as all resources are invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513548480 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ImageneBio Inc (IMA)
For ImageneBio, a biotech focused on immuno-oncology, this chart reflects early-stage drug development. Revenue per employee, if any, likely comes from partnerships, and significant growth is only possible after successful clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ImageneBio-Inc-IMA&v=1772513548509 "Sales chart per company employee ImageneBio Inc (IMA)")
Sales per employee in the market segment - Pharma immune
ImageneBio (formerly Ikena Oncology) is a biotech company focused on developing targeted cancer treatments. It is an R&D-focused business. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive their research team is in advancing research compared to other oncology biotechs.
Sales per employee for the market as a whole
ImageneBio (IMA) / Ikena Oncology is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Currently, its staff consists entirely of researchers. This metric is critical for IMA: it's at zero. Future growth will depend on either successful licensing of their candidates or receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company ImageneBio Inc (IMA)
Ikena Oncology (IMA) is a clinical-stage biotech company working in targeted cancer therapy. Its future depends entirely on the results of its lead candidates. This chart shows how many investors are betting that its scientific platform will fail to produce effective drugs or that its drugs will lose out to competition in the crowded oncology field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ImageneBio-Inc-IMA&v=1772513548605 "Short Shares Chart for the Company ImageneBio Inc (IMA)")
Shares shorted by market segment - Pharma immune
ImageneBio (IMA) (Ikena Oncology) is a biopharmaceutical company focused on immuno-oncology and the development of targeted cancer treatments. This chart summarizes the bearish bets on the immuno-oncology biotech sector. It highlights the overall market pessimism regarding the high level of competition and the failure rate of new cancer treatments.
Shares shorted by the overall market
ImageneBio (IMA) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ImageneBio Inc (IMA)
Ikena Oncology (IMA) is a biotech company operating in the competitive field of immuno-oncology. This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive trial data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ImageneBio-Inc-IMA&v=1772513548664 "RSI 14 indicator chart for the company's stock ImageneBio Inc (IMA)")
RSI 14 Market Segment - Pharma immune
ImageneBio (IMA) (formerly Ikena) is a biotech company focused on cancer (immuno-oncology). The "Pharma-immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether IMA's growth is due to their R&D or whether the entire biotech sector is simply overheated.
RSI 14 for the overall market
ImageneBio (IMA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMA (ImageneBio Inc)
Ikena Oncology (formerly IMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly tumors with Hippo and RAS mutations. This chart shows the speculative average price target from analysts based on their assessment of this R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMA-ImageneBio-Inc&v=1772513548750 "A chart showing analyst consensus forecasts for the expected stock price. IMA (ImageneBio Inc)")
The difference between the consensus estimate and the actual stock price IMA (ImageneBio Inc)
Ikena Oncology (IMA) is a biotech company focused on developing targeted cancer therapies by targeting the Hippo and RAS signaling pathways. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their belief in this complex yet cutting-edge science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMA-ImageneBio-Inc&v=1772513548756 "A chart showing the difference between the consensus forecast and the actual stock price. IMA (ImageneBio Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
ImageneBio (IKENA Oncology) is a biotech company developing precision cancer drugs that target specific genetic mutations in tumors. This chart shows analysts' overall expectations for the immunopharma sector. It reflects their belief in the success of R&D approaches in targeted oncology.
Analysts' consensus forecast for the overall market share price
Ikena Oncology (formerly Kyn Therapeutics) is a biotech company specializing in the development of targeted therapies for the treatment of cancers caused by specific mutations. This chart shows the overall risk appetite. For Ikena, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ImageneBio Inc
ImageneBio (IMA) (likely related to Ikena) is a clinical-stage biotech focused on precision oncology. They are developing targeted therapies against difficult cancer targets. This chart represents pure R&D value. Its valuation is not tied to current revenue but reflects investors' faith in their scientific platform and the data from their early (and very risky) clinical trials.
AKIMA Market Segment Index - Pharma immune
ImageneBio (IKENA Oncology) is a biotech company specializing in the development of targeted therapies for oncology, focusing on the Hippo and RAS signaling pathways. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Ikena's performance compares to the sector average.
The AKIM Index for the overall market
Ikena Oncology (formerly Imagene) is a biotech company developing targeted cancer therapies that target signaling pathways (HIPPO). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends and risk appetite in the sector.
